The U.S. Food and Drug Administration (FDA) has designated Fast Track status
to a new therapeutic drug therapy for the treatment of malignant pleural
mesothelioma (MPM) in patients with unresectable NF2-deficient tumors.
The drug, IK-930, was granted Orphan Drug designation by the FDA earlier
IK-930 was developed by Ikena Oncology, Inc. as a TEAD inhibitor which
targets the Hippo signaling transduction pathway (HSTP) to disrupt gene
and protein function in NF2-deficient tumor cancers to slow or halt cancer
growth. It is estimated that 40% of mesothelioma cases are NF2-deficient.
IK-930 is to be administrated as an oral therapy as a monotherapy for MPM
and is also being researched in Phase 1 clinical trials in the treatment
of a variety of cancers with mutations in the HSTP including non-small
cell lung cancer, soft tissue sarcoma and other cancers that are NF2 deficient
or express YAP1 or TAZ gene fusions.
For more information on the Phase 1 Clinical Trial for IK-930 visit
Also, please visit Ikena Oncology’s June 22
press release and the
National Library of Medicine.